Freitag MM, Zocholl D, Meyer EL, Gold SM, Roig MB, De Smedt H, Posch M, König F; EU‐PEARL MDD Investigators. Design Considerations for a Phase II Platform Trial in Major Depressive Disorder. Pharmaceutical Statistics 2025 Sep-Oct;24(5):e70025. doi: 10.1002/pst.70025.

Transforming the evidence landscape in mental health with platform trials

Gold SM, Mäntylä FL, Donoghue K, Brasanac J, Freitag MM, König F, Posch M, Ramos-Quiroga JA, Benedetti F, Köhler-Forsberg O, Grootendorst N, Hoogendijk W, Pariante CM, Katz ER, Webb S, Lennox B, Furukawa TA, Otte C (2025). Transforming the evidence landscape in mental health with platform trials. Nature Mental Health 3, 276-285. https://doi.org/10.1038/s44220-025-00391-w

Current state-of-the-art and gaps in platform trials

Koenig F, Spiertz C, Millar D, Rodríguez-Navarro S, Machín N, Van Dessel A, Genescà J, Pericàs JM, Posch M; EU-PEARL Consortium (2023). Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL. EClinicalMedicine. 2023 Dec 26;67:102384. doi: 10.1016/j.eclinm.2023.102384.

Platform trials and the future of evaluating therapeutic behavioral interventions

Gold SM, Bofill-Roig M, Miranda JJ, Pariante C, Posch M, Otte C (2022). Platform trials and the future of evaluating therapeutic behavioral interventions. Nature Reviews Psychology 1(1):7-8. doi: 10.1038/s44159-021-00012-0

Sforzini L, et al. (2021). A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry 2021 Dec 15. doi: 10.1038/s41380-021-01381-x.